Business Wire

TX-FLUENCE

Share
Fluence Broad Spectrum LED Lighting Selected for New High-Tech Quarantine Greenhouse in the Netherlands

Fluence by OSRAM (Fluence) has been selected by Wageningen University & Research (WUR) as the lighting provider for Serre Red, the university’s new, high-tech quarantine greenhouse. Serre Red will be used for critical research on plant diseases—caused by viruses, bacteria, fungi and parasitic nematodes—including quarantine pathogens, as well as research on genetically modified organisms.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200526005096/en/

Built by Bosman van Zaal, Serre Red is one of the most advanced quarantine research facilities constructed to date. It features 63 compartments, ranging from 15 to 52 square meters with individual climate control, air filtering and access locks. Extensive technical equipment has been installed in a corridor sunk below ground level to avoid excess shade. Other features of the fully electric greenhouse include insulated double glazing, external shading, heat/cold storage and autoclaving, which sterilizes all materials including water and waste before leaving the greenhouse.

Broad spectrum lighting: Choosing LED over HPS

To reduce the influence of artificial light on their experiments, WUR’s researchers required broad spectrum lighting. Unifarm, the university’s greenhouse and field research facility, ran a market consultation during November and December 2019, then selected four manufacturers from a tender in January 2020. Fluence was granted the order in April after the four potential solutions were examined by WUR’s scientific committee.

“Traditionally, our greenhouses are equipped with HPS lighting,” said Dolf Straathof, head of Unifarm. “As we want to eliminate any influences that artificial lighting could have on experiments, we looked for a solution that came closest to the spectrum that our scientific team specified as optimal.”

“Fluence was one of those consulted, and they proposed higher light levels than we initially specified, which concurred with recommendations from our researchers,” Straathof continued. “The PhysioSpec® solution that Fluence proposed also fit our spectral requirements. In the end, Fluence offered us the best possible solution and exceeded our requirements for uniformity, offering the highest uniformity for a mix of low and tall crops throughout all compartments.”

Optimizing light levels and uniformity

Each compartment will have individual lighting controls, linked to the Hoogendoorn climate control system.

“This is the first time WUR has chosen LED, and specifically broad spectrum LED, as their standard lighting solution for a research greenhouse at Unifarm,” said Theo Tekstra, Fluence’s technical director in Europe, the Middle East and Africa and lead for the project’s design and implementation. “LED solutions have the added advantage that they can be controlled without change in spectrum or loss of efficiency, offering constant light levels and optimal daily light integral. By using our compact VYPR 2x2 full spectrum LED fixtures with the new compact PSU drivers and VYPR reflectors, we minimize shading and optimize overall uniformity. We are extremely proud that our solution was selected as the best in the tender and that we were awarded the contract for this prestigious project.”

Critical research for the world’s growers

Fluence supports, sponsors and collaborates on horticultural research projects throughout the world, including its membership in the Wageningen Research Club of 100—part of the WUR Business Unit for Greenhouse Horticulture in Bleiswijk.

The spread of viral infections—such as the tomato brown rugose fruit virus (ToBRFV)—remains a top concern for growers throughout the world. The new Serre Red facility enables WUR to expand and intensify its research capabilities, maintaining its position as a world leader in research on horticultural crop pathogens.

“ToBRFV currently threatens tomato, bell pepper and chili pepper crops throughout the globe, causing most production greenhouses to close to visitors and creating increased costs for growers through extensive disinfection and other precautionary measures,” said Dr. Theoharis Ouzounis, horticultural scientist at Fluence. “There is no treatment other than prevention and pervasive damage has been reported globally. Research into prevention and treatment of viral diseases is extremely important to safeguard our food production.”

For more information about Fluence lighting solutions, visit www.fluence.science .

About Fluence by OSRAM

Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates the most powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, The Netherlands. For more information about Fluence, visit www.fluence.science .

Link to high resolution pictures: www.fluence.science/press-links

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release

At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,

Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release

Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP

Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release

Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through

Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse

Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye